As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance
Blockbuster Potential In Late-Stage Pipeline
Executive Summary
Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.
You may also be interested in...
Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
Moderna Spotlights Lung Delivery As One Of Its mRNA 'Dreams'
The company’s emphasis on artificial intelligence has played a leading role in development of lipid nanoparticles enabling delivery of mRNA to lung tissue under a partnership with Vertex.
Vertex Diabetes Cell Therapy Trial On Hold – As First Patient Free From Insulin Injections
Vertex expresses surprise at the US FDA’s call for a halt, as it reveals an exciting milestone reached - the first trial participant now producing their own insulin.